The new way to fight cancer.
Our genomic technology enables personalized cancer diagnosis and treatment selection. We analyse DNA from blood or other biological samples to tailor medical treatment and care to the individual patient.
Asia accounts for more than half of all new cancer cases in the world, and most cancer deaths occur in Asia. There is extraordinary diversity in the types of cancers and patterns of illness around the world. Our technology is customized to detect genetic mutations that are more prevalent in the Asian populations to prevent and treat cancer in this region.
Our Liquid Biopsy Technology
Lucence develops blood tests that detect cancer more quickly, accurately and cost-effectively. The tests are based on our proprietary amplicon-based liquid biopsy technology, which detects cancer signals in blood more accurately through amplification.
The simpler way to fight cancer
Early detection of cancer
Our liquid biopsy technology can be used for early cancer detection before symptoms show. Most cancers are currently detected in the late stages resulting in poor treatment outcome. The early detection of cancer will greatly improve cancer survival rate and chances of cure.
Benefits of Liquid Biopsy
Non-invasive. Requires only a single draw of blood
Results back in days for timely treatment
Detects clinically actionable genetic mutations to improve cancer diagnosis and treatment selection
Our Core Innovative Technology
Lucence’s proprietary AmpliMARK™ technology powers our flagship liquid biopsy test – LiquidHALLMARK®, the world’s first blood test that detects both cancer-causing genes and viruses in order to match patients to the best treatment.
AmpliMARK™ is an amplicon-based sequencing technology with sensitivity and specificity of up to 99.9%. We invented this technology to detect cancer signals in blood with higher accuracy by signal amplification.
Our technology detects genomic alterations in the cancer, including somatic mutations, microsatellite instability (MSI) and viral DNA, from circulating tumor DNA (ctDNA) in blood. It is combined with our AI-powered clinical analytics engine SunTzu.AI™ to maximize treatment options for the patient.
The improved accuracy and sensitivity of cancer detection by amplification will be a key foundation of early detection. We are now developing a test for the early detection of multiple cancers founded on this technology towards our vision of zero avoidable cancer deaths.
Our tests are clinically validated for accuracy and kept up to date with the latest clinical findings to provide the best possible diagnostic tests.
Our molecular diagnostics laboratory in Singapore is ISO 15189 accredited. We are licensed by the Ministry of Health (Singapore) as a Clinical Laboratory (Licence No. 17I0039/1/172) under the Private Hospital and Medical Clinics Act.
Our laboratory results are benchmarked with leading quality control agencies to match international standards and provide quality assurance to our customers.